GETUG-AFU 31: a phase I/II multicentre study evaluating the safety and efficacy of salvage stereotactic radiation in patients with intraprostatic tumour recurrence after external radiation therapy-study protocol.
Fiche publication
Date publication
août 2019
Journal
BMJ open
Auteurs
Membres identifiés du Cancéropôle Est :
Pr CORMIER Luc
Tous les auteurs :
Pasquier D, Le Deley MC, Tresch E, Cormier L, Duterque M, Nenan S, Lartigau E
Lien Pubmed
Résumé
Prostate cancer is the third most important cancer in terms of mortality in men. No standard local treatment exists for patients with an intraprostatic recurrence after radiotherapy. Stereotatic body radiotherapy (SBRT) could be a curative treatment for local recurrence. The phase I/II primary objective is the selection of the recommended dose for salvage-SBRT and to estimate the efficacy.
Mots clés
prostate cancer, recurrent prostate cancer, stereotactic body radiation therapy
Référence
BMJ Open. 2019 Aug 2;9(8):e026666